J&J’s Topamax Cleared For Seizure Monotherapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson subsidiary Ortho-McNeil's anti-convulsant Topamax (topiramate) cleared FDA June 29 for the supplemental indication of initial monotherapy for seizures